BAB 5

KESIMPULAN DAN SARAN

5.1   Kesimpulan

Berdasarkan hasil dari kajian literatur pada 9 artikel ilmiah terkait dengan efektivitas dan efek samping memantine pada pasien alzheimer yang dilaksanakan mulai bulan Juli hingga November 2022 dapat disimpulkan bahwa:

1.   Efektivitas yang dilaporkan pada kajian pustaka ini adalah :

    a.   Empat artikel melaporkan adanya perbaikan fungsi kognitif pada penggunaan memantine dan satu artikel melaporkan penggunaan memantine tidak dapat memperbaiki fungsi kognitif pasien alzheimer yang dilihat dari skor MMSE yang dihasilkan.

    b.   Satu artikel melaporkan adanya perbaikan fungsi kognitif pada penggunaan memantine dan Satu artikel melaporkan penggunaan memantine tidak dapat memperbaiki fungsi kognitif pasien alzheimer yang dilihat dari skor ADAS-Cog yang dihasilkan.

2.   Enam artikel melaporkan adanya memiliki efek samping mual, muntah dan diare yang terjadi pada beberapa pasien.

5.2   Saran

1.   Berdasarkan kajian literatur yang telah dilakukan disarankan perlu dilakukan penelitian lain berdasarkan perubahan fungsi afektif dan perbaikan aktivitas fisik dalam kegiatan sehari-hari pasien yang menggunakan terapi memantine.

2. Perlu dilaksanakan penelitian lebih lanjut untuk melihat efek samping yang ditimbulkan pada saat pasien diberikan terapi memantine, selain gangguan saluran pencernaan (mual, muntah, dan diare).

DAFTAR PUSTAKA

Alzheimer Association 2019, 2019 Alzheimer's disease facts and figures, *Alzheimer's Dement*,**15(3)**:321-387.

Alzheimer Association 2020, 2020 Alzheimer's disease facts and figures, *Alzheimer's Dement*,**16(3)** :391-460.

Alzheimer's Association 2021, 2021 Alzheimer's disease facts and figures special report Race, Ethnicity and Alzheimer's in America. *Alzheimers Dement*;**17(3)** :327-406.

Arevalo-Rodriguez I, Smailagic N, Ciapponi A., 2013, Mini-Mental state examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI), *Cochrane Database Syst Rev*,**9(10)**: 20-34

Balsis S, Benge JF, Lowe DA, Geraci L, Doody RS., 2015, How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?, *Clin Neuropsychol*,**29(7)**: 1002-1009.

Blanco-Silvente, L., Capellà, D., Garre-Olmo, J., Vilalta-Franch, J., Castells, X., 2018, Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients, *BMC geriatrics*, **18(1)**: 168-176.

Brenowitz WD, Hubbard RA, Keene CD., 2017, Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample, *Alzheimer's Dement*,**13(6)** :654-662.

Calhoun A., King C,, Khoury R, Grossberg GT., 2018, An evaluation of memantine ER donepezil for the treatment of Alzheimer's disease, *Expert Opin Pharmacother*,**19(15)** :1711-1717.

Cao Y, Qian L, Yu W, Li T, Mao S, Han G., 2020, Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer's disease and chronic obstructive pulmonary disease: a retrospective observational study, *J Int Med Res*,**48(2)**: 23-34

Deardorff WJ, Grossberg GT., 2016, A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease, *Drug Des Devel Ther*,**10(2)**:3267-3279.

DiPiro, T.J., 2020, *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh edition, New York: The Mcgraw Hill Companies.

Djulbegovic B, Guyatt GH., 2017., Progress in evidence-based medicine: a quarter century on, *Lancet*, **390(10092)**:415-423.

Dou, K. X., Tan, M. S., Tan, C. C., Cao, X. P., Hou, X. H., Guo, Q. H., Tan, L., Mok, V., Yu, J. T., 2018, Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials, *Alzheimer's research and therapy*, **10(1)**, 126-134

Fox C, Crugel M, Maidment I., 2012, Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial, *PLoS One*,**7(5)**: 23-34

Grochowalski, J. H., Liu, Y., and Siedlecki, K. L., 2016, Examining the reliability of ADAS-Cog change scores, *Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition*, **23(5)**:513–529,

Grossberg GT, Alva G, Hendrix S, Ellison N, Kane MC, Edwards J., 2018, Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease, *Alzheimer Dis Assoc Disord*,**32(3)**:173-178.

Grossberg GT, Manes F, Allegri RF., 2013, The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe alzheimer's disease taking cholinesterase inhibitors, *CNS Drugs*,**27(6)**: 469-478.

Holthoff V, Ferris S, Gauthier S., 2013 Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study, *Int J Geriatr Psychiatry*,**28(2)**: 164-172.

Howard R, McShane R, Lindesay J., 2012, Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease, *N Engl J Med*,**366(10)**: 893-903.

Jarvis, B., Figgitt, D. P., 2003, Memantine, *Drugs and aging*, **20(6)**: 465–478.

Kametani F, Hasegawa M., 2018, Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease, *Front Neurosci*, **23(1)**: 11-23

Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G., 2016, Therapies for Prevention and Treatment of Alzheimer's Disease, *Biomed Res Int*, **3(2)**: 34-40

Mulimani PS., 2017, Evidence-based practice and the evidence pyramid: A 21st century orthodontic odyssey, *Am J Orthod Dentofac Orthop*.,**152(1)**: 1-8.

Moher D, Liberati A, Tetzlaff J, Altman DG., 2009, Methods of systematic reviews and meta-analysis preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.

Kametani F, Hasegawa M., 2018, Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease, *Front Neurosci*.

Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N., 2017, Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis, *J Alzheimer's Dis*,**60(2)**: 401-425.

Kueper JK, Speechley M, Montero-Odasso M., 2018, The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations: A Narrative Review, *J Alzheimer's Dis*.,**63(2)**: 423-444.

Kuns B, Rosani A, Varghese D., 2021, Memantine. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500025/ , diakses pada 01 Maret 2022

Matsuzono K, Yamashita T, Ohta Y., 2015, Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II), *J Alzheimer's Dis*.,**47(2)**:487-493.

Murti PB., 2005, Pengantar Evidence-Based Medicine, *Pengantar Evidence-Based Med*., Published online:19-23. https://fk.uns.ac.id/static/materi/Pengantar_EBM_Prof_Bhisma_Murti.pdf

Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D., 2014, Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: Results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan, *Expert Opin Pharmacother*,**15(7)**: 913-925.

Reich E, Arias E, Torres C., 2003, Memantine in Alzheimer's disease. *Alzheimer's Dement*, **9(4)**: 1333-1341.

Samad F, Saeed Z, Hasan Z, Fahim MF., 2018, Evidence based medicine; evidence based medicine perceptions of undergraduate medical students in Karachi, Professional Med J, **25(6)**: 896-902,

Santana, I., Duro, D., Lemos, R., Costa, V., Pereira, M., Simões, M. R., Freitas, S., 2016, Mini-Mental State Examination: Avaliação dos Novos Dados Normativos no Rastreio e Diagnóstico do Défice Cognitivo [Mini-Mental State Examination: Screening and Diagnosis of Cognitive Decline, Using New Normative Data]. *Acta medica portuguesa*, **29(4)**: 240–248.

Saxton J, Hofbauer RK, Woodward M., 2012, Memantine and functional communication in Alzheimer's disease: Results of a 12-week, international, randomized clinical trial, *J Alzheimer's Dis*,**28(1)**:23-34

Thakur A, Chun YS, October N, Yang HO, Maharaj V., 2019, Potential of South African medicinal plants targeting the reduction of Aβ42 protein as a treatment of Alzheimer's disease, *J Ethnopharmacol*, **23(2)**: 363-373.

Tumbelaka AR., 2002, Evidence-based Medicine (EBM),**3(4)**:247-248.

Ulep MG, Saraon SK, Mclea S., 2020, Alzheimer Disease, *TJNP J Nurse Pract*,**14(3)**: 129-135.

Verma, N., Beretvas, S. N., Pascual, B., Masdeu, J. C., Markey, M. K., 2015, New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials, *Alzheimer's research and therapy*, **7(1)**: 64-60

Zhang N, Wei C, Du H, Shi FD, Cheng Y., 2015, The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients, *Dement Geriatr Cogn Disord*.;**40(1-2)**: 85-93.